The mTOR signalling pathway in human cancer

Area of Science:

• Molecular Biology
• Cellular Signaling
• Oncology

Background:

• The mammalian target of rapamycin (mTOR) is a key kinase regulating cell growth, proliferation, and survival.
• mTOR exists in two complexes, mTORC1 and mTORC2, with distinct functions and regulation.
• Dysregulation of the mTOR pathway is implicated in various cancers, notably melanoma.

Purpose of the Study:

• To review the molecular mechanisms of mTOR signaling, including upstream activators and downstream effectors.
• To explore the role of mTOR in cancer development and progression, with a focus on melanoma.
• To survey current and emerging therapeutic strategies targeting the mTOR pathway.

Main Methods:

• Literature review of research on mTOR signaling pathways.
• Analysis of molecular mechanisms underlying mTOR activation and function.
• Examination of the role of mTOR in cancer pathogenesis, particularly melanoma.

Main Results:

• mTORC1 regulates mRNA translation and is activated by growth factors, nutrients, and stress signals.
• mTORC2 influences the actin cytoskeleton and activates AKT.
• Aberrations in mTOR pathway components are common in cancers, driving tumor progression.

Conclusions:

• The mTOR pathway is a critical regulator of cell homeostasis and a significant contributor to cancer development.
• mTOR inhibitors, including rapamycin analogs and small molecules, show promise as anti-cancer therapeutics.
• Targeting mTOR offers a viable strategy for treating various cancers, especially melanoma.